Amitava N Mukherjee, S. Joshi, Ips Oberoi, Bhaskar Das, P. Bhushan, Sanjai Kumar Srivastava, KD Tripathi, A. Desai
{"title":"UC-II、透明质酸钠和姜黄素在膝关节骨性关节炎中的临床疗效和耐受性——CAPE研究:一项多中心、前瞻性、真实世界证据研究","authors":"Amitava N Mukherjee, S. Joshi, Ips Oberoi, Bhaskar Das, P. Bhushan, Sanjai Kumar Srivastava, KD Tripathi, A. Desai","doi":"10.22271/ortho.2023.v9.i2b.3358","DOIUrl":null,"url":null,"abstract":"Background: Osteoarthritis (OA) is a degenerative joint disease that results in the breakdown of cartilage, causing pain, stiffness, and decreased range of motion in the affected joints. It is a common form of arthritis, particularly in older adults. Undenatured type II collagen (UC-II) is a nutritional supplement which has been found to be effective in treating OA. Objective: To determine the efficacy and safety of UC-II, sodium hyaluronate, and curcumin in treating knee OA. Materials and Methods: 813 patients with knee OA were enrolled in the study. Subjects received a capsule containing 40 mg UC-II, 80 mg sodium hyaluronate and 200 mg curcumin once daily for three months. The Western Ontario and McMaster Osteoarthritis Index (WOMAC) evaluated pain, joint stiffness, and physical functions. A Visual Analog Scale (VAS) was used to assess the severity of the initial pain. Moreover, clinical symptom scores and patient and physician global assessments were evaluated. The patients were assessed before the treatment and three months after the initiation of the treatment. Results: The WOMAC scores for pain, stiffness, and function, as well as the VAS score, were significantly improved (P< 0.05) in subjects after three months compared to the baseline. There was a 73.51% improvement in the total WOMAC scores and a 69.92% improvement in the VAS scores. There was a significant reduction in clinical symptoms, and global assessments of treatment by patients and physicians based on overall efficacy were favourable after the three-month treatment. Conclusion : The study showed that UC-II, sodium hyaluronate and curcumin in combination effectively improve the symptoms of OA and should be positively considered for the symptomatic management of OA.","PeriodicalId":14302,"journal":{"name":"International Journal of Orthopaedics Sciences","volume":"69 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical effectiveness and tolerability of UC-II, sodium hyaluronate, and curcumin in osteoarthritis of the knee – CAPE Study: A multicentre, Prospective, real-world evidence study\",\"authors\":\"Amitava N Mukherjee, S. Joshi, Ips Oberoi, Bhaskar Das, P. Bhushan, Sanjai Kumar Srivastava, KD Tripathi, A. Desai\",\"doi\":\"10.22271/ortho.2023.v9.i2b.3358\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Osteoarthritis (OA) is a degenerative joint disease that results in the breakdown of cartilage, causing pain, stiffness, and decreased range of motion in the affected joints. It is a common form of arthritis, particularly in older adults. Undenatured type II collagen (UC-II) is a nutritional supplement which has been found to be effective in treating OA. Objective: To determine the efficacy and safety of UC-II, sodium hyaluronate, and curcumin in treating knee OA. Materials and Methods: 813 patients with knee OA were enrolled in the study. Subjects received a capsule containing 40 mg UC-II, 80 mg sodium hyaluronate and 200 mg curcumin once daily for three months. The Western Ontario and McMaster Osteoarthritis Index (WOMAC) evaluated pain, joint stiffness, and physical functions. A Visual Analog Scale (VAS) was used to assess the severity of the initial pain. Moreover, clinical symptom scores and patient and physician global assessments were evaluated. The patients were assessed before the treatment and three months after the initiation of the treatment. Results: The WOMAC scores for pain, stiffness, and function, as well as the VAS score, were significantly improved (P< 0.05) in subjects after three months compared to the baseline. There was a 73.51% improvement in the total WOMAC scores and a 69.92% improvement in the VAS scores. There was a significant reduction in clinical symptoms, and global assessments of treatment by patients and physicians based on overall efficacy were favourable after the three-month treatment. Conclusion : The study showed that UC-II, sodium hyaluronate and curcumin in combination effectively improve the symptoms of OA and should be positively considered for the symptomatic management of OA.\",\"PeriodicalId\":14302,\"journal\":{\"name\":\"International Journal of Orthopaedics Sciences\",\"volume\":\"69 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Orthopaedics Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22271/ortho.2023.v9.i2b.3358\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Orthopaedics Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22271/ortho.2023.v9.i2b.3358","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:骨关节炎(OA)是一种退行性关节疾病,导致软骨破裂,引起关节疼痛、僵硬和活动范围减小。这是一种常见的关节炎,尤其是在老年人中。未变性II型胶原蛋白(UC-II)是一种营养补充剂,已被发现对治疗OA有效。目的:探讨UC-II、透明质酸钠和姜黄素治疗膝关节炎的疗效和安全性。材料与方法:813例膝关节OA患者入组研究。受试者服用含有40毫克UC-II、80毫克透明质酸钠和200毫克姜黄素的胶囊,每天一次,持续三个月。Western Ontario and McMaster Osteoarthritis Index (WOMAC)评估疼痛、关节僵硬和身体功能。采用视觉模拟量表(VAS)评估初始疼痛的严重程度。此外,临床症状评分和患者和医生的整体评估进行了评估。在治疗前和治疗开始后三个月对患者进行评估。结果:3个月后患者疼痛、僵硬、功能的WOMAC评分及VAS评分较基线均有显著改善(P< 0.05)。WOMAC总分提高了73.51%,VAS评分提高了69.92%。临床症状显著减轻,在三个月的治疗后,患者和医生根据总体疗效对治疗进行的总体评估是有利的。结论:本研究表明UC-II、透明质酸钠、姜黄素联合应用能有效改善OA的症状,在OA的症状管理中应积极考虑。
Clinical effectiveness and tolerability of UC-II, sodium hyaluronate, and curcumin in osteoarthritis of the knee – CAPE Study: A multicentre, Prospective, real-world evidence study
Background: Osteoarthritis (OA) is a degenerative joint disease that results in the breakdown of cartilage, causing pain, stiffness, and decreased range of motion in the affected joints. It is a common form of arthritis, particularly in older adults. Undenatured type II collagen (UC-II) is a nutritional supplement which has been found to be effective in treating OA. Objective: To determine the efficacy and safety of UC-II, sodium hyaluronate, and curcumin in treating knee OA. Materials and Methods: 813 patients with knee OA were enrolled in the study. Subjects received a capsule containing 40 mg UC-II, 80 mg sodium hyaluronate and 200 mg curcumin once daily for three months. The Western Ontario and McMaster Osteoarthritis Index (WOMAC) evaluated pain, joint stiffness, and physical functions. A Visual Analog Scale (VAS) was used to assess the severity of the initial pain. Moreover, clinical symptom scores and patient and physician global assessments were evaluated. The patients were assessed before the treatment and three months after the initiation of the treatment. Results: The WOMAC scores for pain, stiffness, and function, as well as the VAS score, were significantly improved (P< 0.05) in subjects after three months compared to the baseline. There was a 73.51% improvement in the total WOMAC scores and a 69.92% improvement in the VAS scores. There was a significant reduction in clinical symptoms, and global assessments of treatment by patients and physicians based on overall efficacy were favourable after the three-month treatment. Conclusion : The study showed that UC-II, sodium hyaluronate and curcumin in combination effectively improve the symptoms of OA and should be positively considered for the symptomatic management of OA.